Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Specific estrogen receptor modulators (SERMs)].

Florence Trémollières1, Patrice Lopes

  • 1Unité de ménopause et maladies osseuses métaboliques, service d'endocrinologie, CHU Rangueil, Toulouse (31).

Presse Medicale (Paris, France : 1983)
|October 3, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vascular risk at menopause: The importance of a cardio-gynecological program.

Maturitas·2026
Same author

Prescribing practices for menopausal hormone therapy in France in 2025: A national online survey (MENOPRAT).

Maturitas·2026
Same author

Venous Thromboembolism Risk Associated With Relugolix-estradiol-norethisterone Acetate Combination Therapy.

Journal of the Endocrine Society·2026
Same author

Efficacy and safety of daridorexant for the treatment of insomnia disorder in women of menopausal transition age: Insights from a randomized controlled trial.

Maturitas·2026
Same author

[Understanding menopause. Pathophysiology of hot flashes].

Medecine sciences : M/S·2026
Same author

Women's experience of premature ovarian insufficiency (POI) diagnosis: update on actual practices and women's follow-up (EMPOIHER Study).

Menopause (New York, N.Y.)·2025

Selective estrogen receptor modulators (SERMs) like raloxifene offer bone and cardiovascular benefits without gynecological stimulation. Raloxifene effectively prevents osteoporosis and reduces breast cancer risk in postmenopausal women.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Oncology

Background:

  • Selective estrogen receptor modulators (SERMs) are non-steroidal compounds with tissue-specific estrogenic and anti-estrogenic effects.
  • Tamoxifen, an early SERM, is used for breast cancer but carries risks like endometrial hyperplasia.
  • Raloxifene represents a newer generation of SERMs, developed to mitigate side effects while retaining beneficial estrogenic actions.

Purpose of the Study:

  • To evaluate the efficacy and safety of raloxifene in preventing postmenopausal bone loss and vertebral fractures.
  • To assess raloxifene's effects on cardiovascular markers and gynecological health.
  • To determine raloxifene's therapeutic role in managing menopausal women, particularly in osteoporosis prevention.

Main Methods:

Related Experiment Videos

  • Review of randomized, double-blind, placebo-controlled studies investigating raloxifene's effects.
  • Analysis of pre-clinical and clinical data on raloxifene's pharmacological profile.
  • Comparison of raloxifene's outcomes with hormone replacement therapy (HRT) and placebo.

    • Main Results:

    • Raloxifene demonstrated significant efficacy in preventing postmenopausal bone loss and reducing vertebral fracture incidence.
    • Favorable effects on lipid profiles and no increase in C-reactive protein were observed.
    • Good endometrial tolerance and a significant reduction in breast cancer incidence were noted in osteoporotic women.

    Conclusions:

    • Raloxifene is effective for osteoporosis prevention in postmenopausal women, offering benefits for bone health and cardiovascular markers.
    • Its favorable gynecological safety profile makes it suitable for women with contraindications to HRT or benign breast/uterine conditions.
    • While not ideal for climacteric symptom management, raloxifene serves as a valuable option for long-term osteoporosis management and potentially as a successor to HRT.